To include your compound in the COVID-19 Resource Center, submit it here.

Peginesatide: Additional Phase III data

Additional data from the open-label, U.S. Phase III EMERALD 2 trial in 823 dialysis patients showed that that the proportion of peginesatide-treated patients whose Hb remained within the target range of 10-12 g/dL during 4-week periods in the

Read the full 385 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE